Rebecca Alice Gardner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca Alice Gardner has a total of 463 co-authors. Here are the top co-authors by number of shared publications:
- Julie R. Park
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
29 shared publications - Wenjun Huang
Seattle Children's Research Institute
26 shared publications - Ashley L. Wilson
Seattle Children's Research Institute, Seattle, WA
25 shared publications - Michael C. Jensen
Seattle Children’s Therapeutics, Seattle, Washington 98101, United States
25 shared publications - Christopher Brown
Seattle Children’s Therapeutics , Seattle, Washington
21 shared publications - Kristy Seidel
Seattle Children's Research Institute 7
21 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in Research Square
First-in-human quad-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are lethal pediatric central nervous system (CNS) tumors with a median survival of 11 months. Despite advancements in translating chimeric antigen receptor (CAR) T cells for these patients, efficacy may be constrained by antigen heterogeneity and immune escape. We conducted a first-in-human, phase 1 trial (BrainChild-04; NCT05768880) evaluating repetitive intracerebroventricular (ICV) administration of a multi-antigen targeting CAR T cell product directed against B7-H3, EGFR806, HER2 and IL13Rα2 (quad-CAR T cells) for children and young adults with DIPG/pontine DMG (Arm A) and recurrent or refractory CNS tumors (Arm B). Here we report results from Arm A. Primary endpoints were feasibility, safety, and determination of the maximally tolerated dose regimen (MTDR). Secondary endpoints included CAR T cell distribution and preliminary clinical activity. Correlative analyses assessed CAR T cell kinetics and cytokine dynamics in cerebrospinal fluid (CSF). Twenty-six patients were enrolled with 100% manufacturing success rate. Twenty-one patients received at least one infusion (median 8/patient, range 3-56). No dose-limiting toxicities occurred in the dose-finding period, and treatment was tolerable with predominantly grade 1-2 adverse events, including fever (95%), headache (86%), and fatigue (81%). One dose-limiting toxicity (acoustic nerve disorder) occurred outside the evaluation window. Repetitive ICV dosing was feasible, and most of the infused patients (86%) initiated two or more treatment courses (median 4). CAR T cells were detected in CSF in 100% of patients, across serial courses in 76% of patients, with evidence of detection across sequential courses, particularly at higher dose levels. Cytokine profiling demonstrated dynamic immune activation within the CNS. Median survival from initial CAR T infusion was 8.6 months (95% CI: 5.2-10.3). All deaths were due to disease progression. Repetitive ICV administration of quad-CAR T cells is feasible and tolerable in children and young adults with DIPG/DMG. This study represents the first clinical application of quad-antigen targeting CAR T cells and confirmed feasibility in manufacturing and preliminary evidence of biologic activity in the CNS. These findings support further evaluation of multi-antigen CAR T strategies to address tumor heterogeneity of antigen expression as a likely barrier to CAR T cell efficacy in patients with CNS tumors.
- 27 October 2026
- Published by Springer Nature in Research Square
Open AccessFirst-in-human quad-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are lethal pediatric central nervous system (CNS) tumors with a median survival of 11 months. Despite advancements in translating chimeric antigen receptor (CAR) T cells for these patients, efficacy may be constrained by antigen heterogeneity and immune escape. We conducted a first-in-human, phase 1 trial (BrainChild-04; NCT05768880) evaluating repetitive intracerebroventricular (ICV) administration of a multi-antigen targeting CAR T cell product directed against B7-H3, EGFR806, HER2 and IL13Rα2 (quad-CAR T cells) for children and young adults with DIPG/pontine DMG (Arm A) and recurrent or refractory CNS tumors (Arm B). Here we report results from Arm A. Primary endpoints were feasibility, safety, and determination of the maximally tolerated dose regimen (MTDR). Secondary endpoints included CAR T cell distribution and preliminary clinical activity. Correlative analyses assessed CAR T cell kinetics and cytokine dynamics in cerebrospinal fluid (CSF). Twenty-six patients were enrolled with 100% manufacturing success rate. Twenty-one patients received at least one infusion (median 8/patient, range 3-56). No dose-limiting toxicities occurred in the dose-finding period, and treatment was tolerable with predominantly grade 1-2 adverse events, including fever (95%), headache (86%), and fatigue (81%). One dose-limiting toxicity (acoustic nerve disorder) occurred outside the evaluation window. Repetitive ICV dosing was feasible, and most of the infused patients (86%) initiated two or more treatment courses (median 4). CAR T cells were detected in CSF in 100% of patients, across serial courses in 76% of patients, with evidence of detection across sequential courses, particularly at higher dose levels. Cytokine profiling demonstrated dynamic immune activation within the CNS. Median survival from initial CAR T infusion was 8.6 months (95% CI: 5.2-10.3). All deaths were due to disease progression. Repetitive ICV administration of quad-CAR T cells is feasible and tolerable in children and young adults with DIPG/DMG. This study represents the first clinical application of quad-antigen targeting CAR T cells and confirmed feasibility in manufacturing and preliminary evidence of biologic activity in the CNS. These findings support further evaluation of multi-antigen CAR T strategies to address tumor heterogeneity of antigen expression as a likely barrier to CAR T cell efficacy in patients with CNS tumors.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S1 – Demographics and Baseline Characteristics for All Enrolled Subjects.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S1 – Demographics and Baseline Characteristics for All Enrolled Subjects.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S2. Representativeness of Study Participants.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S2. Representativeness of Study Participants.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S4 – Toxicities Possibly, Probably or Definitely Related to First Infusion of CAR T Cells.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S4 – Toxicities Possibly, Probably or Definitely Related to First Infusion of CAR T Cells.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S3 – Bridging Therapy Received.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S3 – Bridging Therapy Received.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S1. A)Gating strategy of peripheral blood CAR T cell detection by flow cytometry. B)Gating strategy for paired 2GS/3GS products evaluating differentiation state and activation/exhaustion state by flow cytometry.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S1. A)Gating strategy of peripheral blood CAR T cell detection by flow cytometry. B)Gating strategy for paired 2GS/3GS products evaluating differentiation state and activation/exhaustion state by flow cytometry.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S2. Differential expression by flow cytometry of differentiation (A + B), activation/exhaustion markers (C + D) of paired 2GS and 3GS products for the 6 patients who had both products generated, separated by CD4 (A + C) and CD8 (B + D) experiments, showing no statistical differences between paired 2GS and 3GS products.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S2. Differential expression by flow cytometry of differentiation (A + B), activation/exhaustion markers (C + D) of paired 2GS and 3GS products for the 6 patients who had both products generated, separated by CD4 (A + C) and CD8 (B + D) experiments, showing no statistical differences between paired 2GS and 3GS products.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S3. Kidney biopsy of S16 demonstrating A) no inflammatory infiltrate on H&E sections, B)intact CD171+ renal tubules and C) no CD3+ infiltrate.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S3. Kidney biopsy of S16 demonstrating A) no inflammatory infiltrate on H&E sections, B)intact CD171+ renal tubules and C) no CD3+ infiltrate.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S4. Pre- and post-CAR T peripheral blood cytokine profiling comparing cytokines for patients on Arm A and Arm B, showing no statistical differences between groups.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S4. Pre- and post-CAR T peripheral blood cytokine profiling comparing cytokines for patients on Arm A and Arm B, showing no statistical differences between groups.